Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

AV7909

Vaccine (Peptide vaccine) · Immune activation, directed at Bacillus anthracis antigen · developed by Emergent BioSolutions

Phase 3 Most advanced trial (none active)

EBS Developer

2 Registered trials

What is AV7909?

AV7909 is an anthrax vaccine combining Anthrax Vaccine Adsorbed (AVA) with CPG 7909, an immunostimulatory oligodeoxynucleotide adjuvant. It is designed to enhance immune response against Bacillus anthracis and is studied for post-exposure prophylaxis of anthrax infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Vaccine (Peptide vaccine)
Targets: Bacillus anthracis antigen (antigen)
Mechanism: Immune activation, directed at Bacillus anthracis antigen
Pathways: immune_activation
Therapy area: Infectious disease
Developer: Emergent BioSolutions (EBS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03877926	Phase 3	Anthrax	Completed	EBS
NCT01263691	Phase 1	Bacillus Anthracis (Anthrax) Infection	Completed	EBS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AnthraxBacillus Anthracis (Anthrax) Infection

More from Emergent BioSolutions

AIGIV FDA approved Bacillus anthracis strain V770-NP1-R antigens FDA approved Brincidofovir FDA approved smallpox vaccine live, New York City Board of Health vaccinia strain FDA approved Vaccinia Immune Globulin FDA approved Ad4-EnvC150 Phase 1 Ad4-H5-Vtn Phase 1 Ad4-mgag Phase 1 Ad4-PA-1 Phase 1 Ad4-PA-GPI-1 Phase 1 AIDSVAX B/E Phase 1 Botulinum Antitoxin Heptavalent Phase 1

Sources

ClinicalTrials.gov NCT03877926

Updated Oct 3, 2026. Something wrong or missing? Report it on the EBS page.

Follow EBS, the company behind AV7909

See EBS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EBS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z